Summary of this article
Invesco India's pharma fund NFO closes September 1, 2026.
Minimum lump sum investment starts at just Rs 1,000.
Fund invests across pharmaceutical, hospital, diagnostic, and insurance sectors.
The domestic healthcare ecosystem is witnessing strong investor interest. On a year-to-date basis, the BSE Healthcare Index has gained over 16 per cent. The interest is being driven by structural drivers of growth for India’s healthcare space, such as favourable demographics, increasing healthcare expenditure, expanding insurance penetration, and rising global pharmaceutical leadership.
Amid these long-term growth trends and rising investor interest, Invesco Mutual Fund has announced the launch of the Invesco India Pharma and Healthcare Fund. The fund seeks to provide investors with exposure to opportunities across the healthcare value chain.
Invesco India Pharma and Healthcare Fund: Key Dates
Invesco India Pharma and Healthcare Fund’s New Fund Offer (NFO) opened for subscription on August 18, 2026. The window is scheduled to officially close on September 1, 2026.
Invesco India Pharma and Healthcare Fund: Minimum Investment and Exit Load
During the NFO period, the minimum lump sum investment amount for Invesco India Pharma and Healthcare Fund is Rs 1,000, and in multiples of Re 1 thereafter. For Systematic Investment Plan (SIP) investments, the minimum application amount is Rs 100, and in multiples of Re 1 thereafter. The fund will charge an exit load of 0.50 per cent for units redeemed or switched out on or before 3 months from the date of allotment, while no exit load will be charged if units are redeemed after the 3-month mark.
What Does Invesco India Pharma and Healthcare Fund Invest In?
According to the offer document for the scheme, it invests predominantly in equity and equity-related instruments of companies across the broader pharma and healthcare ecosystem.
The portfolio allocations include pharmaceutical companies, hospitals, diagnostics, Contract Development and Manufacturing Organisations (CDMOs), and Contract Research Organisations (CROs). Additionally, the fund covers investments into medical devices, healthcare services, insurance, and other allied segments.
Notably, the returns of the scheme are benchmarked against the BSE Healthcare TRI. Investors should also note that the riskometer indicates a "Very High" risk level for both the scheme and its benchmark.
Growth Drivers and Outlook
According to the fund house, India occupies a unique position in the global healthcare ecosystem, supported by manufacturing scale, talent pool, and an expanding innovation footprint.
According to Invesco ageing demographics, the increasing prevalence of lifestyle diseases, expanding health insurance coverage, and improved healthcare infrastructure are expected to serve as long-term catalysts for the sector’s growth. Additionally, global outsourcing and contract research trends are expected to create sustainable long-term opportunities.
Speaking at the launch, Aditya Khemani, Head of Equity and Fund Manager at Invesco Mutual Fund, highlighted that the investment approach will concentrate on choosing quality businesses with sustainable competitive advantages and strong growth visibility across the ecosystem.
"India's healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub. We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem," Khemani said.
